Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
159 hedge funds and large institutions have $3.13B invested in Karuna Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 64 increasing their positions, 47 reducing their positions, and 12 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
44% more call options, than puts
Call options by funds: $9.5M | Put options by funds: $6.61M
36% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 47
7% more capital invested
Capital invested by funds: $2.93B → $3.13B (+$202M)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
1% less funds holding
Funds holding: 160 → 159 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$15.7M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$15.6M |
| 3 |
Jennison Associates
New York
|
+$10.2M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.63M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$43.4M |
| 2 |
Holocene Advisors
New York
|
-$23M |
| 3 |
CII
Capital International Inc
Los Angeles,
California
|
-$21.8M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$10.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.93M |
KRTX Hedge Fund Activity: Q3 2021 in Review
159 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q3 2021, worth a combined $3.13B — up 6.9% from $2.93B a quarter earlier.
Fund positioning in KRTX was balanced in Q3 2021: 12 funds opened new positions, 12 closed out, 64 added to existing stakes and 47 trimmed.
The largest buyer was State Street, adding an estimated $15.7M. The largest seller was Sands Capital Management, exiting entirely with an estimated $43.4M sold.
- 159 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q3 2021, down from 160 in Q2 2021.
- Funds reported $3.13B of Karuna Therapeutics, Inc. Common Stock stock for Q3 2021, up 6.9% quarter-over-quarter.
- 12 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q3 2021 and 12 closed out, a net change of 0 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q3 2021 was State Street, an estimated $15.7M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q3 2021 was Sands Capital Management, an estimated $43.4M sold.
Based on aggregated 13F filings for Q3 2021.